These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

531 related items for PubMed ID: 16949481

  • 1. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
    Jo SH, Youn TJ, Koo BK, Park JS, Kang HJ, Cho YS, Chung WY, Joo GW, Chae IH, Choi DJ, Oh BH, Lee MM, Park YB, Kim HS.
    J Am Coll Cardiol; 2006 Sep 05; 48(5):924-30. PubMed ID: 16949481
    [Abstract] [Full Text] [Related]

  • 2. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study.
    Mehran R, Nikolsky E, Kirtane AJ, Caixeta A, Wong SC, Teirstein PS, Downey WE, Batchelor WB, Casterella PJ, Kim YH, Fahy M, Dangas GD.
    JACC Cardiovasc Interv; 2009 May 05; 2(5):415-21. PubMed ID: 19463464
    [Abstract] [Full Text] [Related]

  • 3. [Comparison of iodixanol (Visipaque) and ioxaglate (Hexabrix) in coronary angiography and ventriculography: a double-blind randomized study].
    Roriz R, de Gevigney G, Finet G, Nantois-Collet C, Borch KW, Amiel M, Beaune J.
    J Radiol; 1999 Jul 05; 80(7):727-32. PubMed ID: 10431273
    [Abstract] [Full Text] [Related]

  • 4. Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography.
    Shin DH, Choi DJ, Youn TJ, Yoon CH, Suh JW, Kim KI, Cho YS, Cho GY, Chae IH, Kim CH.
    Am J Cardiol; 2011 Jul 15; 108(2):189-94. PubMed ID: 21545991
    [Abstract] [Full Text] [Related]

  • 5. Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media.
    Liss P, Persson PB, Hansell P, Lagerqvist B.
    Kidney Int; 2006 Nov 15; 70(10):1811-7. PubMed ID: 17003814
    [Abstract] [Full Text] [Related]

  • 6. Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy: meta-analysis of randomized, controlled trials.
    From AM, Al Badarin FJ, McDonald FS, Bartholmai BJ, Cha SS, Rihal CS.
    Circ Cardiovasc Interv; 2010 Aug 15; 3(4):351-8. PubMed ID: 20647563
    [Abstract] [Full Text] [Related]

  • 7. One-year results of the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study.
    Giustino G, Baber U, Mastoris I, Vlachojannis GJ, Yu J, Teirstein PS, Downey WE, Batchelor WB, Casterella PJ, Nikolsky E, Wong SC, Theodoropoulos KN, Dangas GD, Mehran R.
    Catheter Cardiovasc Interv; 2016 Mar 15; 87(4):703-9. PubMed ID: 26481591
    [Abstract] [Full Text] [Related]

  • 8. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B, Cheng WJ, Li YF, Cao Z, Yang Q, Zhao YX, Guo YH, Zhou YJ.
    Catheter Cardiovasc Interv; 2008 Dec 01; 72(7):958-65. PubMed ID: 19021282
    [Abstract] [Full Text] [Related]

  • 9. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials.
    Reed M, Meier P, Tamhane UU, Welch KB, Moscucci M, Gurm HS.
    JACC Cardiovasc Interv; 2009 Jul 01; 2(7):645-54. PubMed ID: 19628188
    [Abstract] [Full Text] [Related]

  • 10. A randomized prospective trial of ioxaglate 320 (Hexabrix) vs. iodixanol 320 (Visipaque) in patients undergoing percutaneous coronary intervention.
    Sutton AG, Ashton VJ, Campbell PG, Price DJ, Hall JA, de Belder MA.
    Catheter Cardiovasc Interv; 2002 Nov 01; 57(3):346-52. PubMed ID: 12410513
    [Abstract] [Full Text] [Related]

  • 11. Iodixanol versus iopromide in patients with renal insufficiency undergoing coronary angiography with or without PCI.
    Zhang J, Jiang Y, Rui Q, Chen M, Zhang N, Yang H, Zhou Y.
    Medicine (Baltimore); 2018 May 01; 97(18):e0617. PubMed ID: 29718868
    [Abstract] [Full Text] [Related]

  • 12. Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial.
    Juergens CP, Winter JP, Nguyen-Do P, Lo S, French JK, Hallani H, Fernandes C, Jepson N, Leung DY.
    Intern Med J; 2009 Jan 01; 39(1):25-31. PubMed ID: 18771430
    [Abstract] [Full Text] [Related]

  • 13. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography.
    Thomsen HS, Morcos SK, Erley CM, Grazioli L, Bonomo L, Ni Z, Romano L, Investigators in the Abdominal Computed Tomography: IOMERON 400 Versus VISIPAQUE 320 Enhancement (ACTIVE) Study.
    Invest Radiol; 2008 Mar 01; 43(3):170-8. PubMed ID: 18301313
    [Abstract] [Full Text] [Related]

  • 14. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: A multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators.
    Bertrand ME, Esplugas E, Piessens J, Rasch W.
    Circulation; 2000 Jan 18; 101(2):131-6. PubMed ID: 10637198
    [Abstract] [Full Text] [Related]

  • 15. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media.
    McCullough PA, Bertrand ME, Brinker JA, Stacul F.
    J Am Coll Cardiol; 2006 Aug 15; 48(4):692-9. PubMed ID: 16904536
    [Abstract] [Full Text] [Related]

  • 16. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials.
    Heinrich MC, Häberle L, Müller V, Bautz W, Uder M.
    Radiology; 2009 Jan 15; 250(1):68-86. PubMed ID: 19092091
    [Abstract] [Full Text] [Related]

  • 17. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol.
    Barrett BJ, Katzberg RW, Thomsen HS, Chen N, Sahani D, Soulez G, Heiken JP, Lepanto L, Ni ZH, Ni ZH, Nelson R.
    Invest Radiol; 2006 Nov 15; 41(11):815-21. PubMed ID: 17035872
    [Abstract] [Full Text] [Related]

  • 18. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial.
    Rudnick MR, Davidson C, Laskey W, Stafford JL, Sherwin PF, VALOR Trial Investigators.
    Am Heart J; 2008 Oct 15; 156(4):776-82. PubMed ID: 18946896
    [Abstract] [Full Text] [Related]

  • 19. Nephrotoxic effects in high-risk patients undergoing angiography.
    Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ, Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators.
    N Engl J Med; 2003 Feb 06; 348(6):491-9. PubMed ID: 12571256
    [Abstract] [Full Text] [Related]

  • 20. Renal Insufficiency Following Radiocontrast Exposure Trial (REINFORCE): a randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy.
    Adolph E, Holdt-Lehmann B, Chatterjee T, Paschka S, Prott A, Schneider H, Koerber T, Ince H, Steiner M, Schuff-Werner P, Nienaber CA.
    Coron Artery Dis; 2008 Sep 06; 19(6):413-9. PubMed ID: 18955835
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.